NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

ACVR2A downregulation disrupts the TCF7/c-JUN pathway, impairing trophoblast invasion and proliferation in pre-eclampsia, revealing a genetic susceptibility-associated mechanism of placental ...

Spinal cord injury (SCI) is a devastating, debilitating, and life-altering condition that currently lacks a definitive cure or highly effective treatment ...